By Michael Doane The CEO of a small technology-based company with many groundbreaking patents in its field once asked me what the point was of obtaining patents when the company […]
IPPI Summer 2025 Progress Report
IPPI Spring 2025 Progress Report (March – May 2025) Navigation IPPI Hosted and Co-Hosted Events News & Speaking Engagements Scholarship & Other Writing Greetings from IPPI Research Professor & Executive […]
IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership
IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]
RESTORE, PERA and PREVAIL: Bills that fix problems with the patent system
By Kristen Jakobsen Osenga As the 118th Congress drew to a close at the end of 2024, there was a spate of intellectual property activity on Capitol Hill. I was […]
Announcing IPPI + IPPI Spring 2025 Progress Report
Navigation Announcing IPPI: The IP Policy Institute A Message from Faculty Chair Mark Schultz & Executive Director Joshua Kresh IPPI Spring Progress Report (December 2024-February 2025) IPPI Hosted and Co-Hosted […]
Pharmaceutical “Nominal Patent Life” Versus “Effective Patent Life,” Revisited
By Emily Michiko Morris and Joshua Kresh Executive summary: Many critics of pharmaceutical companies argue that they abuse the patent system through “evergreening” or “thickets” to increase the amount of […]
[Archived Post] Using Economic Models to Evaluate the Efficacy of U.S. Patent Examination
By William Matcham For the Center for Intellectual Property x Innovation Policy blog, in fulfillment of obligations for the Thomas Edison Innovation Law and Policy Fellowship Highlights: Policymakers frequently debate the […]